Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Cmax“
Suchtreffer
Begriffe & Kennungen
Biktarvy · 4.5 · Sofosbuvir: AUC: ↔ Cmax: ↔
Eintrag öffnenBiktarvy · 4.5 · Tenofovir alafenamide: AUC: ↑ 57% Cmax: ↑ 28%
Eintrag öffnenBiktarvy · 4.5 · Tenofovir alafenamide: AUC: ↔ Cmax: ↔
Eintrag öffnenBiktarvy · 4.5 · Velpatasvir: AUC: ↔ Cmin: ↔ Cmax: ↔
Eintrag öffnenBiktarvy · 4.5 · Voxilaprevir: AUC: ↔ Cmin: ↔ Cmax: ↔ Antifungals Voriconazole (300 mg twice daily), Bictegravir: No dose adjus
Eintrag öffnenBosulif · 4.5 · 10 increased bosutinib Cmax by 1.5-fold, and bosutinib AUC in plasma by 2.0-fold, as compared with administrat
Eintrag öffnenBrilique · 4.5 · CYP3A inducers Co-administration of rifampicin with ticagrelor decreased ticagrelor Cmax and AUC by 73% and 86
Eintrag öffnenBrilique · 4.5 · CYP3A inducers Co-administration of rifampicin with ticagrelor decreased ticagrelor Cmax and AUC by 73% and 86
Eintrag öffnenBrilique · 4.5 · CYP3A inducers Co-administration of rifampicin with ticagrelor decreased ticagrelor Cmax and AUC by 73% and 86
Eintrag öffnenBrilique · 4.5 · Rosuvastatin (BCRP substrate) Ticagrelor has been shown to increase rosuvastatin Cmax by approximately 2.5-fol
Eintrag öffnenBrilique · 4.5 · Rosuvastatin (BCRP substrate) Ticagrelor has been shown to increase rosuvastatin Cmax by approximately 2.5-fol
Eintrag öffnenBrilique · 4.5 · Rosuvastatin (BCRP substrate) Ticagrelor has been shown to increase rosuvastatin Cmax by approximately 2.5-fol
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of rifampicin (strong CYP3A inducer) decreased zanubrutinib Cmax by 92% an
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of rifampicin (strong CYP3A inducer) decreased zanubrutinib Cmax by 92% an
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased midazolam (CYP3A substrate) Cmax by 30% and AUC
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased midazolam (CYP3A substrate) Cmax by 30% and AUC
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased omeprazole (CYP2C19 substrate) Cmax by 20% and A
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased omeprazole (CYP2C19 substrate) Cmax by 20% and A
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib increased digoxin (P-gp substrate) Cmax by 34% and AUC by
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib increased digoxin (P-gp substrate) Cmax by 34% and AUC by
Eintrag öffnen